単純ヘルペスウイルス治療市場- 世界の産業規模、シェア、動向、機会、予測、ウイルスタイプ別、治療法別、投与経路別、流通チャネル別、地域別、競合別、2020年～2030年

単純ヘルペスウイルス（HSV）治療の世界市場は、2024年に25億2,000万米ドルと評価され、予測期間中のCAGRは8.05％で、2030年には39億8,000万米ドルに達すると予測されています。

世界の単純ヘルペスウイルス（HSV）治療市場は、製薬・ヘルスケア産業の中でも、HSV感染の世界の持続的流行に牽引され、ダイナミックに発展している分野です。HSVは、主に口唇ヘルペスや性器ヘルペスの原因として知られていますが、その生涯を通じて感染する性質、定期的な発生、潜在的な合併症のために、公衆衛生上の重大な懸念事項であり続けています。認知度と診断率が向上するにつれて、効果的な治療に対する需要は増加の一途をたどっています。例えば、単純ヘルペスウイルス（HSV）感染の有病率は世界的に増加しています。WHOは2023年4月現在、50歳未満の約37億人（人口の約67％）がHSV-1に感染しており、15～49歳の約4億9,100万人がHSV-2に感染していると推定しています。この高い感染率は、効果的な治療管理の必要性を強調しています。HSVの治療オプションは主に抗ウイルス薬であり、決定的な治癒を提供するのではなく、重症度と発生頻度を減少させるように設計されています。これらの抗ウイルス療法は、症状を管理し、感染リスクを低下させ、患者の生活の質を改善するのに役立ちます。市場では、アシクロビル、バラシクロビル、ファムシクロビルなどの経口抗ウイルス剤を含む様々な確立された薬剤が使用されており、これらの薬剤はその有効性と安全性が証明されているため、標準的な治療法となっています。これらに加えて、現在進行中の調査では、治療成績と患者のコンプライアンスを向上させるために、新しい抗ウイルス剤や新しいドラッグデリバリーシステムが研究されています。従来の医薬品に加え、代替療法や補助療法への関心も高まっています。これらには、従来の抗ウイルス薬を補完することを目的とした局所クリーム、免疫療法、自然療法などが含まれます。分子生物学とウイルス学の開発がワクチンと遺伝子治療の開発を促進しており、これらはHSVに対する将来の予防・治療戦略として有望です。

市場促進要因

HSV感染の高い有病率と再発率

主な市場課題

ヘルスケアへのアクセスとインフラの不安定性

主要市場動向

診断イノベーションの成長

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 単純ヘルペスウイルス（HSV）治療の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • ウイルスタイプ別（HSV-1 vs/s HSV-2）
  • 治療法別（薬剤vs.ワクチン）
  • 投与経路別（経口、静脈内、局所）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024年）
• 市場マップ
  • ウイルスタイプ別
  • 治療法別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第7章 北米の単純ヘルペスウイルス（HSV）治療市場の展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州の単純ヘルペスウイルス（HSV）治療市場の展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第9章 アジア太平洋の単純ヘルペスウイルス（HSV）治療市場の展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第10章 南米の単純ヘルペスウイルス（HSV）治療市場の展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカの単純ヘルペスウイルス（HSV）治療市場の展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第14章 競合情勢

• Novartis International AG
• GlaxoSmithKline, plc.
• Sanofi SA
• Mylan N.V.
• Emcure Pharmaceuticals Ltd.
• Glenmark Pharmaceuticals Inc.
• Fresenius Kabi AG
• Apotex Inc.
• Viatris Inc.
• Teva Pharmaceuticals Industries Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Herpes Simplex Virus (HSV) Treatment Market was valued at USD 2.52 billion in 2024 and is expected to reach USD 3.98 billion by 2030 with a CAGR of 8.05% during the forecast period. The Global Herpes Simplex Virus (HSV) Treatment Market is a dynamic and evolving sector within the pharmaceutical and healthcare industries, driven by the persistent prevalence of HSV infections worldwide. HSV, primarily known for causing oral and genital herpes, remains a significant public health concern due to its lifelong nature, periodic outbreaks, and potential complications. As awareness and diagnosis rates improve, the demand for effective treatments continues to grow. For instance, the prevalence of herpes simplex virus (HSV) infection is increasing globally. As of April 2023, WHO estimates that approximately 3.7 billion people under 50-about 67% of the population-live with HSV-1, while around 491 million individuals aged 15 to 49 are infected with HSV-2. This high infection rate underscores the critical need for effective therapeutic management. Treatment options for HSV primarily focus on antiviral medications designed to reduce the severity and frequency of outbreaks rather than offering a definitive cure. These antiviral therapies help manage symptoms, lower transmission risks, and improve the quality of life for patients. The market features a variety of established drugs, including oral antivirals like acyclovir, valacyclovir, and famciclovir, which have become standard treatments due to their proven efficacy and safety profiles. Alongside these, ongoing research is exploring new antiviral agents and novel drug delivery systems to enhance treatment outcomes and patient compliance. In addition to traditional pharmaceuticals, the market is witnessing an increase in interest towards alternative and adjunct therapies. These include topical creams, immunotherapies, and natural remedies aimed at complementing conventional antiviral drugs. Advances in molecular biology and virology are fostering the development of vaccines and gene therapies, which hold promise for future preventive and therapeutic strategies against HSV.

Key Market Drivers

High Prevalence and Recurrence of HSV Infections

The high prevalence and recurrence of Herpes Simplex Virus (HSV) infections play a critical role in shaping the global treatment market. For instance, in September 2022, researchers at Fred Hutchinson Cancer Center discovered a potential herpes cure using gene therapy. Their experimental treatment successfully targeted latent infections in animals, reducing viral activity and significantly suppressing transmission rates to other animals. This breakthrough offers promising advancements toward more effective HSV treatments and possible long-term solutions.

HSV is one of the most common viral infections worldwide, with a large portion of the population infected, often unknowingly. This widespread prevalence creates a steady and ongoing demand for treatment options. Many individuals experience periodic outbreaks throughout their lives, as the virus remains dormant in nerve cells and can reactivate under certain conditions such as stress or weakened immunity. The recurrent nature of HSV infections means patients frequently require long-term management rather than a one-time treatment. This need drives continuous consumption of antiviral medications that help control symptoms and reduce the frequency of outbreaks. The persistent presence of HSV in a significant segment of the population ensures sustained demand for both episodic and suppressive therapies. Episodic treatment focuses on reducing the severity and duration of outbreaks when they occur, while suppressive treatment aims to prevent or minimize recurrence, offering patients greater control over their condition. Healthcare providers recognize the importance of managing recurrent HSV infections to reduce transmission risks and improve patients' quality of life. This recognition encourages ongoing prescriptions and innovations in antiviral drugs and formulations that provide better efficacy, safety, and convenience. The repeated need for treatment creates a stable and growing market, encouraging pharmaceutical companies to invest in research and development of newer therapies. The combination of a large infected population and frequent recurrence ensures the HSV treatment market remains robust, with continued opportunities for expanding access and improving treatment options worldwide.

Key Market Challenges

Variability in healthcare access and infrastructure

Variability in healthcare access and infrastructure presents a significant challenge for the Global Herpes Simplex Virus (HSV) Treatment Market. In many regions, especially low- and middle-income countries, limited healthcare resources restrict the availability of diagnostic tools and antiviral medications essential for effective HSV management. This disparity leads to underdiagnosis and undertreatment of HSV infections, despite their widespread prevalence. Access to reliable laboratory facilities capable of performing accurate HSV testing is often inadequate in underserved areas. Without proper diagnosis, many patients remain unaware of their infection status, which hinders timely treatment and increases the risk of transmission. The lack of trained healthcare professionals who can provide counseling and prescribe appropriate therapies further limits effective management. Economic constraints also affect patients' ability to afford ongoing antiviral treatments. In regions with limited healthcare funding or out-of-pocket payment systems, many individuals may forgo treatment due to cost, which suppresses market growth. In contrast, developed countries with advanced healthcare infrastructure offer better access to diagnostics and a wider range of treatment options, driving higher market demand. The variability in healthcare systems across countries creates challenges for pharmaceutical companies attempting to establish a uniform market strategy. Regulatory environments, reimbursement policies, and distribution networks differ greatly, affecting how easily treatments reach patients. Companies must adapt to local conditions, which can increase operational complexity and costs.

Improving healthcare infrastructure and access is critical to expanding the HSV treatment market globally. Efforts to enhance diagnostic capabilities, affordability, and healthcare provider training are essential to ensure patients in all regions can receive timely and effective treatment.

Key Market Trends

Growth in diagnostic innovations

Growth in diagnostic innovations plays a crucial role in shaping the Global Herpes Simplex Virus (HSV) Treatment Market by enabling earlier and more accurate detection of infections. Advanced diagnostic technologies have improved the ability of healthcare providers to identify HSV even in asymptomatic patients, which expands the pool of individuals seeking treatment. Early diagnosis is essential for timely intervention, reducing transmission rates, and improving patient outcomes. Modern diagnostic tools such as polymerase chain reaction (PCR) assays offer high sensitivity and specificity compared to traditional methods. These molecular techniques allow for rapid detection of viral DNA, enabling clinicians to distinguish between HSV-1 and HSV-2 types. Type-specific diagnosis is important because it informs treatment decisions and counseling regarding disease prognosis and transmission risks. Point-of-care testing devices are becoming more widely available, facilitating diagnosis in various clinical settings without the need for complex laboratory infrastructure. Serological tests have also improved, providing better accuracy in detecting antibodies to HSV. These developments help identify individuals with latent infections who may benefit from suppressive therapy. The availability of more reliable and user-friendly tests encourages routine screening, particularly in populations at higher risk for HSV infections.

Improved diagnostics drive market growth by increasing the number of diagnosed cases requiring treatment. Pharmaceutical companies benefit from this trend as heightened detection rates translate into greater demand for antiviral drugs. Laboratories and diagnostic companies are investing in developing faster, cheaper, and more accessible tests to meet growing clinical needs. Enhanced diagnostics support personalized treatment approaches, allowing healthcare providers to tailor therapies based on infection status and type. This trend is integral to expanding the overall HSV treatment market worldwide.

Key Market Players

• Novartis International AG
• GlaxoSmithKline, plc.
• Sanofi SA
• Mylan N.V.
• Emcure Pharmaceuticals Ltd.
• Glenmark Pharmaceuticals Inc.
• Fresenius Kabi AG
• Apotex Inc.
• Viatris Inc.
• Teva Pharmaceuticals Industries Ltd

Report Scope:

In this report, the Global Herpes Simplex Virus (HSV) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Herpes Simplex Virus (HSV) Treatment Market, By Virus Type:

• HSV-1
• HSV-2

Herpes Simplex Virus (HSV) Treatment Market, By Treatment:

• Drugs
• Vaccines

Herpes Simplex Virus (HSV) Treatment Market, By Route of Administration:

• Oral
• Intravenous
• Topical

Herpes Simplex Virus (HSV) Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Herpes Simplex Virus (HSV) Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Herpes Simplex Virus (HSV) Treatment Market.

Available Customizations:

Global Herpes Simplex Virus (HSV) Treatment Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Application
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Herpes Simplex Virus (HSV) Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Virus Type (HSV-1 v/s HSV-2)
  • 6.2.2. By Treatment (Drugs v/s Vaccines)
    • 6.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
    • 6.2.2.2. By Vaccines (Simplirix, Others)
  • 6.2.3. By Route of Administration (Oral, Intravenous, Topical)
  • 6.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Virus Type
  • 6.3.2. By Treatment
  • 6.3.3. By Route of Administration
  • 6.3.4. By Distribution Channel
  • 6.3.5. By Region

7. North America Herpes Simplex Virus (HSV) Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Virus Type (HSV-1 v/s HSV-2)
  • 7.2.2. By Treatment (Drugs v/s Vaccines)
    • 7.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
    • 7.2.2.2. By Vaccines (Simplirix, Others)
  • 7.2.3. By Route of Administration (Oral, Intravenous, Topical)
  • 7.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Virus Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Canada Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Virus Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Mexico Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Virus Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel

8. Europe Herpes Simplex Virus (HSV) Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Virus Type (HSV-1 v/s HSV-2)
  • 8.2.2. By Treatment (Drugs v/s Vaccines)
    • 8.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
    • 8.2.2.2. By Vaccines (Simplirix, Others)
  • 8.2.3. By Route of Administration (Oral, Intravenous, Topical)
  • 8.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Virus Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Germany Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Virus Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. United Kingdom Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Virus Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. Italy Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Virus Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Spain Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Virus Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Asia-Pacific Herpes Simplex Virus (HSV) Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Virus Type (HSV-1 v/s HSV-2)
  • 9.2.2. By Treatment (Drugs v/s Vaccines)
    • 9.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
    • 9.2.2.2. By Vaccines (Simplirix, Others)
  • 9.2.3. By Route of Administration (Oral, Intravenous, Topical)
  • 9.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Virus Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. India Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Virus Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Japan Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Virus Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel
  • 9.3.4. South Korea Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Virus Type
      • 9.3.4.2.2. By Treatment
      • 9.3.4.2.3. By Route of Administration
      • 9.3.4.2.4. By Distribution Channel
  • 9.3.5. Australia Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Virus Type
      • 9.3.5.2.2. By Treatment
      • 9.3.5.2.3. By Route of Administration
      • 9.3.5.2.4. By Distribution Channel

10. South America Herpes Simplex Virus (HSV) Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Virus Type (HSV-1 v/s HSV-2)
  • 10.2.2. By Treatment (Drugs v/s Vaccines)
    • 10.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
    • 10.2.2.2. By Vaccines (Simplirix, Others)
  • 10.2.3. By Route of Administration (Oral, Intravenous, Topical)
  • 10.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Virus Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Argentina Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Virus Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Colombia Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Virus Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Middle East and Africa Herpes Simplex Virus (HSV) Treatment Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Virus Type (HSV-1 v/s HSV-2)
  • 11.2.2. By Treatment (Drugs v/s Vaccines)
    • 11.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
    • 11.2.2.2. By Vaccines (Simplirix, Others)
  • 11.2.3. By Route of Administration (Oral, Intravenous, Topical)
  • 11.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Virus Type
      • 11.3.1.2.2. By Treatment
      • 11.3.1.2.3. By Route of Administration
      • 11.3.1.2.4. By Distribution Channel
  • 11.3.2. Saudi Arabia Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Virus Type
      • 11.3.2.2.2. By Treatment
      • 11.3.2.2.3. By Route of Administration
      • 11.3.2.2.4. By Distribution Channel
  • 11.3.3. UAE Herpes Simplex Virus (HSV) Treatment Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Virus Type
      • 11.3.3.2.2. By Treatment
      • 11.3.3.2.3. By Route of Administration
      • 11.3.3.2.4. By Distribution Channel

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Competitive Landscape

• 14.1. Novartis International AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As reported)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. GlaxoSmithKline, plc.
• 14.3. Sanofi SA
• 14.4. Mylan N.V.
• 14.5. Emcure Pharmaceuticals Ltd.
• 14.6. Glenmark Pharmaceuticals Inc.
• 14.7. Fresenius Kabi AG
• 14.8. Apotex Inc.
• 14.9. Viatris Inc.
• 14.10. Teva Pharmaceuticals Industries Ltd

15. Strategic Recommendations

16. About Us & Disclaimer